Critical appraisal of paroxetine for the treatment of vasomotor symptoms

Dana G Carroll1,2
Katelin M Lisenby1,2
Tracy L Carter3

1Department of Pharmacy Practice, Harrison School of Pharmacy, Auburn University, Auburn, AL, USA; 2Department of Family Medicine, College of Community Health Sciences, University of Alabama, University Medical Center, Tuscaloosa, AL, USA; 3Department of Pharmacy, DCH Regional Medical Center, Tuscaloosa, AL, USA

Background: Vasomotor symptoms (VMS), characterized by hot flashes and night sweats, are the most commonly reported symptoms associated with estrogen deficiency during menopause and occur in up to 70% of women. The goal of treatment is to reduce the frequency and severity of symptoms. Although hormone therapy (HT) is generally recommended as first-line treatment, it is not appropriate for all patients. Antidepressants, specifically selective serotonin reuptake inhibitors, have been evaluated and utilized internationally for alternative treatment for VMS. In 2013, paroxetine mesylate (Brisdelle®) received a US Food and Drug Administration-labeled indication for moderate-to-severe hot flashes, making it the first nonhormonal treatment for VMS associated with menopause. The objective of this review is to critically evaluate available clinical data regarding the efficacy and safety of paroxetine for the treatment of VMS in menopausal women.

Methods: MEDLINE, PubMed, and Google Scholar were searched using the keywords paroxetine, vasomotor symptoms, hot flashes, and menopause. Searches were limited to humans, English language, and clinical trial design with a primary outcome of hot flash/vasomotor changes.

Results: Paroxetine (hydrochloride and mesylate) has been associated with a 33%–67% reduction in hot flash frequency with 6–12 weeks of treatment compared to 13.7%–37.8% reductions with placebo in patients both with and without a history of breast cancer. It was also associated with significant reductions in hot flash severity. Benefits of treatment persisted through 24 weeks in the study of the longest duration. Most adverse effects reported were of mild-to-moderate severity, with improved tolerability associated with lower doses (7.5–12.5 mg/day).

Conclusion: Paroxetine is a safe and effective therapy for the treatment of VMS during menopause. Paroxetine (7.5–12.5 mg/day) should be considered a first-line therapy option for VMS in patients when HT is either inappropriate or intolerable.

Keywords: paroxetine, vasomotor symptoms, hot flashes, menopause

Background

The onset of menopause can be an extremely challenging life change for many women. The timing of when natural menopause occurs is affected by race, ethnicity, and lifestyle.1 The average age of onset in industrialized nations is in the early 50s but occurs several years earlier in developing countries.1,2 Therefore, most women spend one-third of their lifespan in a postmenopausal state. Menopause is defined as the permanent loss of menses for 1 year following ovarian failure, which results in an estrogen- and progesterone-deficient state.2,3 This decline in estrogen and progesterone levels is known to contribute to several signs and symptoms associated with menopause, such as hot flashes, vaginal atrophy, dyspareunia, memory problems, mood changes, and insomnia.2,4 These physical and psychological changes can affect the quality of life of up to 85% menopausal women.2,4
The most common and troublesome symptoms are the hot flashes and night sweats, known as vasomotor symptoms (VMS).\textsuperscript{2–4} VMS occur in \textgreater 70\% of menopausal women, and one-third of women first experience hot flashes during perimenopause, the years leading up to menopause.\textsuperscript{2,3} Hot flashes frequently manifest as flushing, warmth around the face and neck, perspiration, and chills. Hot flashes are further characterized by a sudden onset, either without warning or after a trigger such as caffeine or stress, and generally last 1–5 minutes. These events can occur multiple times daily and usually persist for 1–4 years, although they may continue for \textgreater 10 years in some women.\textsuperscript{2–4} Although the pathophysiology of hot flashes has not been fully elucidated, it has been suggested that a decline in estrogen and progesterone levels triggers alterations to the neuroendocrine system, including changes in serotonin and norepinephrine levels, and leads to thermoregulatory dysfunction in the hypothalamus.\textsuperscript{7,3} Changes in serotonin and norepinephrine are associated with increases in core body temperatures and narrowing of the thermoregulatory zone.\textsuperscript{4}

Treatment of VMS is directed at reducing both the severity and the frequency of hot flashes.\textsuperscript{5} Hormone therapy (HT) is considered to be the most effective treatment for VMS and is therefore recognized as a first-line option.\textsuperscript{2,3} It is recommended for the management of VMS by the American Association of Clinical Endocrinologists (AACE) and the American College of Obstetricians and Gynecologists (ACOG).\textsuperscript{2,3} HT is also supported in a global consensus statement endorsed by the North American Menopause Society (NAMS), the European Menopause and Andropause Society, the International Menopause Society (IMS), the Asia Pacific Menopause Federation, the American Society of Reproductive Medicine, the Endocrine Society, and the International Osteoporosis Foundation.\textsuperscript{6}

Although HT is noted to be efficacious, its use is not without concerns.\textsuperscript{2,3,6} The safety concerns of HT were well established after the Women’s Health Initiative trials were published in 2002.\textsuperscript{2,7–9} Women considering HT must evaluate the increased risks of thromboembolism and breast cancer. The absolute risk increase is low but varies based on the use of estrogen monotherapy or therapy in combination with progestin, baseline risks, age, years since menopause, and possibly route of administration.\textsuperscript{2} HT is contraindicated in women with a history of thromboembolism and breast cancer.\textsuperscript{3,3–7} Both of these serious adverse events are rare in patients \textless 60 years of age or those within 10 years of menopause; therefore, HT is a suitable option for most women.\textsuperscript{7} However, alternative treatments are needed for women in whom HT is either inappropriate or intolerable, those having a higher baseline risk for adverse events, or those preferring not to use HT.

Antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs), are recognized as an acceptable alternative treatment for the management of VMS associated with menopause.\textsuperscript{3,7} ACOG, AACE, IMS, and NAMS all suggest that SSRIs constitute an effective alternative to HT for the treatment of VMS with a growing body of evidence but note the need for more studies, particularly in direct comparison with HT.\textsuperscript{2,3,5,7} SSRIs contribute to VMS management through two proposed mechanisms. These include decreasing blood flow to the skin to counter the vasodilation during flushing and lowering core body temperature through central vasodilation to negate the effects that occur during menopause due to the narrowed thermoregulatory zone.\textsuperscript{4}

There has been an increasing amount of evidence to support the use of several SSRIs for VMS management, with paroxetine being one of the most extensively studied.\textsuperscript{10–15} In 2013, the US Food and Drug Administration (FDA) approved paroxetine mesylate (Brisdelle®; Noven Therapeutics, LLC, Miami, FL, USA) for the treatment of moderate-to-severe VMS. The approval was based largely on the results of two recently published randomized controlled trials (RCTs) and made paroxetine mesylate the first nonhormonal treatment indicated for VMS associated with menopause.\textsuperscript{10,16} The evidence for the use of paroxetine (as the hydrochloride [HCl] and mesylate salts) in the management of VMS is examined in this review.

Search criteria

This is a systematic review to evaluate the use of paroxetine to treat VMS associated with menopause (natural, chemotherapy induced, or surgically induced). We searched the following databases using these search terms in various combinations.

- Medline: “paroxetine” [MESH], “vasomotor” [MESH], “hot flashes” [MESH], and “menopause” [MESH]
- PubMed: “paroxetine”, “vasomotor”, “hot flashes”, and “menopause”
- Google Scholar: “paroxetine”, “vasomotor”, “hot flashes”, and “menopause”

Inclusion criteria included English language trials, prospective and retrospective cohorts or case–control trials, prospective RCTs, paroxetine vs placebo or active treatment, and a primary outcome of hot flash/vasomotor changes. We identified ten trials,\textsuperscript{10–15,17–20} four of which were excluded.\textsuperscript{17–20} The reasons for exclusion included the assessment of nonclinical outcomes (one assessing pharmacokinetic properties,\textsuperscript{17} one
assessing brain-derived neurotrophic factor, \(^{18}\) and one assessing cytokine levels\(^{19}\)), whereas one did not assess hot flashes or VMS as the primary outcome.\(^{20}\)

**Assessments of VMS in clinical trials**

Studies assessing VMS typically require enrolled patients to log the frequency of hot flash occurrences into a diary on a daily basis to collect data. In addition, some studies require patients to both rank the severity and record the duration of each hot flash in the diary. Investigators can then use this information to assess the frequency and severity of hot flashes. While this can be clinically useful information to report a change in frequency, more validated and useful instruments are available to assess changes in hot flashes in menopausal women. The Hot Flash Composite Score has patients rank the severity of their hot flashes (which is given a numerical score) multiplied by the frequency and a daily score is calculated.\(^{11}\) (Refer Table 1 for more specific details on each instrument.) Higher scores with this assessment tool correlate with more severe VMS.\(^{11}\) The Greene Climacteric Score (GCS) is a validated instrument utilized to assess VMS and assesses four domains (psychological, somatic, VMS, and sexual dysfunction).\(^{11}\) Overall scores can range from 0 to 63, with higher scores indicating more severe symptoms. The VMS domain subscore in the GCS ranges from 0 to 6, with higher scores indicating more severe symptoms.\(^{13}\) Another instrument, the Weekly Hot Flash Severity Index, assesses and calculates a score on a weekly basis.\(^{10}\) Higher scores are associated with more severe VMS.\(^{10}\)

While most studies assess actual changes in the frequency and/or severity of hot flashes as the primary outcome, there are other aspects that may be assessed as valid secondary outcomes. One of the most popular aspects assessed as a secondary outcome is the patient perception and satisfaction with changes in hot flash occurrence and/or severity after initiating therapy. One validated instrument utilized to assess women’s perceptions of improvement in their hot flashes is the Patient Global Impression of Improvement (PGI-I).\(^{10,16}\) The instruments previously discussed are utilized in the studies included in this review.

**Study populations primarily with breast cancer**

Paroxetine HCl initially was studied in a small, open-label pilot study (n=30) by Stearns et al\(^{13}\) in women with a history of breast cancer. Seventy-four percent age of patients enrolled were experiencing \(\geq 5\) hot flashes per day. All patients took

| **Table 1** Instruments used in trials to assess vasomotor symptoms (VMS) |
|------------------|------------------|------------------|
| **Instrument** | **Score** | **Clinical interpretation** |
| Hot Flash Composite Score\(^{11}\) | Each level of hot flash severity (mild =1, moderate =2, severe =3, very severe =4) \(\times\) daily number of hot flashes in that category. A daily score is compiled from the sum of the four resulting values. | Higher scores correlate with more severe symptoms |
| Greene Climacteric Scale\(^{12}\) (validated) | Consists of 21 items scored as not at all =0, a little =1, quite a bit =2, extremely =3 to assess four domains: psychological (items 1–11; score range 0–33), somatic (12–18; 0–21), VMS (19–20; 0–6), and sexual dysfunction (21; 0–3) | Score range: 0–63 (higher scores correlate with more severe symptoms); VMS subscore: 0–6 (scores of 0–2 indicate no to mild hot flashes, and scores of 3–6 indicate moderate-to-severe hot flashes) |
| Weekly hot flash severity score\(^{10}\) | Mild = sensation of heat without sweating, able to continue activity. Moderate = sensation of heat with sweating, causes cessation of activity. Severe = sensation of heat with sweating, causes cessation of activity. \((2 \times \text{number of moderate}) + (3 \times \text{number of severe}) \div \text{total number of moderate and severe} \) | Higher scores correlate with more severe symptoms |
| Patient Global Impression of Improvement\(^{11,16}\) (validated) | “Compared to before starting the study medication, how would you describe your hot flushes now?” Satisfied = (1) Very much better or (2) Much better. Unsatisfied = otherwise | (1) Very much better, (2) Much better, (3) A little better, (4) No change, (5) A little worse, (6) Much worse, (7) Very much worse |

Paroxetine in the treatment of vasomotor symptoms
10 mg of paroxetine HCl daily for 1 week and then 20 mg daily for 5 weeks. The primary outcomes assessed were change in hot flash frequency and hot flash score (frequency × intensity). Hot flash frequency was decreased by 67% (confidence interval [CI]: 56%–79%) at the end of 6 weeks and hot flash scores decreased by 75% (CI: 66%–85%). At the end of the study, 83% (n = 25) chose to continue paroxetine HCl even after the study was completed. Nine percent age (n = 3) dropped out before the trial was complete due to somnolence (n = 2) and anxiety (n = 1). The most common adverse effects reported were somnolence, dry mouth, nausea, and dizziness (Table 2). Limitations of this study include the following: open-label study design, very small study population, study population exclusive for breast cancer survivors, and short duration.

Another small open-label pilot study (n = 13) followed this initial study, and it too was conducted exclusively in a breast cancer survivor population.14 These patients had to experience hot flashes of at least moderate intensity (≥3 on a scale of 1–5) to be enrolled. Patients were assigned to take paroxetine HCl 10 mg daily for 3 days, followed by 20 mg daily thereafter for 6 weeks. The primary outcome assessed was change in the hot flash severity. Hot flash severity was 3.62 ± 0.51 at baseline and 2.08 ± 1.32 at the end of the study (P = 0.002). Adverse effects were not reported. Limitations of this study include the following: open-label study design, very small study population, study population consisting exclusively breast cancer survivors, and short duration.

In 2005, Stearns et al15 conducted a double-blind, randomized, controlled, crossover study in 151 menopausal women, with the majority being breast cancer survivors. This study consisted of a 4-week active treatment period, a 4-week placebo period, and a 1-week washout period between the crossovers. There were four groups within the study: 10 mg paroxetine HCl followed by placebo, placebo followed by 10 mg paroxetine HCl, 20 mg paroxetine HCl followed by placebo, and placebo followed by 20 mg paroxetine HCl. The primary outcomes were change in hot flash frequency and hot flash composite scores. The baseline mean daily hot flash frequency ranged from 6.9 to 7.8 among the four groups and was of moderate intensity. Hot flash frequency was decreased by 40.6% (standard error [SE]: 5.1) vs 13.7% (SE: 5.6), P = 0.0006, with 10 mg paroxetine HCl vs placebo. Hot flash frequency was significantly decreased by 51.7% (SE: 5.3) vs 26.6% (SE: 7.0), P = 0.0002, with 20 mg paroxetine HCl vs placebo. Composite scores also significantly decreased with 10 mg and 20 mg of paroxetine HCl vs placebo arms (Table 2 shows the complete results). Forty-four (29%) patients were...

---

**Table 2** Summary of the literature on paroxetine for treatment of vasomotor symptoms in patients primarily with a history of breast cancer

<table>
<thead>
<tr>
<th>Study design</th>
<th>Treatment regimen and duration</th>
<th>Patient characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Open-label study</td>
<td>Paroxetine HCl 10 mg daily for 1 week, followed by 20 mg daily for 5 weeks.</td>
<td>History of breast cancer with disease status: mean age 52 years, mean hot flashes/day: seven to eight.</td>
</tr>
<tr>
<td>Open-label study</td>
<td>Paroxetine HCl 10 mg daily for 3 days.</td>
<td>History of breast cancer with disease status: mean age 35 years, mean hot flashes/day: seven to eight.</td>
</tr>
<tr>
<td>Randomized, double-blind, placebo-controlled crossover study</td>
<td>Paroxetine HCl 10 mg daily for 1 week and then 20 mg daily thereafter for 6 weeks.</td>
<td>History of breast cancer with disease status: mean age 52 years, mean hot flashes/day: NR.</td>
</tr>
<tr>
<td>Randomized, placebo-controlled crossover study</td>
<td>Paroxetine HCl 20 mg daily.</td>
<td>History of breast cancer with disease status: mean age 35 years, mean hot flashes/day: NR.</td>
</tr>
</tbody>
</table>

**Efficacy results**

- Hot flash frequency reduction: 40.6% (SE: 5.1%) with paroxetine 10 mg vs 13.7% (SE: 5.6%) with placebo, P = 0.0006; 51.7% (SE: 5.3%) with paroxetine 20 mg vs 26.6% (SE: 7.0%), P = 0.0002.
- Hot flash composite score reduction: 45.6% (SE: 5.8%) with paroxetine, 10 mg vs 17.5% (SE: 6.9%) with placebo, P = 0.0002; 17.5% (SE: 6.9%) with placebo, P = 0.0002 with paroxetine 20 mg vs 28.5% (SE: 7.9%), P = 0.001.

**Limitations**

- Open-label study design.
- Very small study population.
- Study population consisting exclusively breast cancer survivors.
- Short duration.

**Abbreviations:** CI, confidence interval; NR, not reported; SE, standard error; HCl, hydrochloride.
lost to follow-up for incomplete or missing data, and 17 (11%) patients withdrew due to adverse effects. The majority of the withdrawals were in the 20 mg paroxetine HCl group (n=13), with fewer in the 10 mg paroxetine HCl group (n=4). The most commonly reported adverse effects were drowsiness and nausea. Strengths of this study included the trial design that utilized patients as their own control and the utilization of a hot flash diary to record frequency and severity. Limitations of this study included the small study population, short study duration, lack of a dose titration, only a single-week washout period, significant loss to follow-up, high withdrawal rates, and study population that consisted largely of breast cancer survivors (81%), with 64% of those taking tamoxifen or raloxifene, which are associated with hot flashes.

**Summary of paroxetine use in populations primarily with a history of breast cancer**

In the summarized literature, paroxetine HCl was associated with a 40%–67% reduction in hot flash frequency with 4–6 weeks of treatment compared to 14%–27% reductions with placebo (Table 2). It was also associated with significant reductions in hot flash severity. The benefits of paroxetine HCl on VMS were observed within 1–2 weeks of therapy and were shown to persist throughout a 6-week treatment duration in this patient population. These trials showed both doses of paroxetine HCl – 10 mg and 20 mg – to be effective for VMS, but the 10 mg dose was better tolerated.

Tamoxifen, a selective estrogen receptor modulator (SERM), is a targeted chemotherapeutic agent that competitively inhibits estrogen. For the 75% of breast cancers that are estrogen receptor positive, tamoxifen may be considered at any stage but it is frequently used as adjuvant treatment for 2–6 years after primary treatment to prevent recurrence. The medication can be given to both pre- and postmenopausal women. Up to 80% of patients who take tamoxifen experience hot flashes as an adverse event, necessitating the need to consider treatment for VMS.

There is a significant drug interaction between tamoxifen and paroxetine that clinicians should be aware of in this patient population. Paroxetine inhibits CYP2D6, a cytochrome P450 enzyme that converts the prodrug tamoxifen to active metabolites, and thus may decrease the effectiveness of tamoxifen. An in vivo study of 12 women found that paroxetine decreased the mean serum concentration of the active metabolite endoxifen by 6.9 ng/mL (CI: 2.7–11.2 ng/mL; P=0.004). A study of 80 newly diagnosed breast cancer patients found that women taking potent CYP2D6 inhibitors, including paroxetine, had levels of endoxifen that were 58% lower (CI: −86.1 to −19.5; P=0.0025).

Beyond the pharmacokinetic studies, a cohort study of 2,430 women breast cancer survivors who were prescribed an SSRI and tamoxifen were assessed for all-cause mortality and breast cancer mortality. Women in this cohort who were prescribed and took paroxetine had increased breast cancer mortality. The risk was increased further based on the proportion of time tamoxifen administration overlapped with paroxetine administration (overlap percentage of 25% for administration time produced 24% increase, 50% overlap resulted in a 54% increase, and 75% overlap generated 91% increase; P<0.05 for all). On the basis of the results from this study, there would be an additional death from breast cancer for every 19.7 patients who simultaneously received paroxetine and tamoxifen 41% of the time (median overlap in this study population). The risk with more extensive overlap would be even greater. This increased risk was not found with the other SSRIs investigated in the study.

As a result of this interaction resulting in decreased efficacy of tamoxifen, both the National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology recommend using caution with concomitant use of paroxetine and tamoxifen. Furthermore, the NCCN and IMS specifically prefer citalopram and venlafaxine over paroxetine and fluoxetine.

**Study populations primarily without breast cancer**

The safety and efficacy of paroxetine for the treatment of VMS in postmenopausal women primarily without a history of breast cancer have been evaluated in four randomized, double-blind, placebo-controlled trials. The first RCT to evaluate the role of paroxetine for the treatment of VMS in a menopausal population without a history of breast cancer was conducted in 165 women with at least two to three hot flashes per day or 14 hot flashes per week. Patients were randomized to receive paroxetine HCl controlled release (CR) (12.5 mg or 25 mg) or placebo daily for 6 weeks after a 1-week run-in phase. The primary objective evaluated was hot flash composite score (Table 1). Patients had a mean of 6.7 hot flashes per day, and only 7.3% had a history of breast cancer. When compared to placebo, both the 12.5 mg (62.2% vs 37.8%; P=0.007) and 25 mg (64.6% vs 37.8%; P=0.03) paroxetine HCl CR groups demonstrated a significant reduction in mean hot flashes composite scores at 6 weeks. The majority of adverse events reported (58.3% in paroxetine vs 53.6% in placebo) were of mild-to-moderate
severity and consistent with the established adverse effects of paroxetine. The most common adverse events associated with paroxetine HCl CR therapy were headache, dizziness, nausea, and insomnia, with lower frequencies in the 12.5 mg group than the 25 mg group. Strengths of this trial include a population of subjects who were not primarily breast cancer survivors, a low percentage (7.3%) of patients taking SERM therapy, the evaluation of paroxetine 12.5 mg and 25 mg doses, and the utilization of a CR formulation, which is better tolerated. Limitations include a small sample size studied over a short duration, lack of dose titration, and a limited racial group representation (87% white).

The second RCT trial was conducted in 56 perimenopausal and postmenopausal patients who reported VMS after discontinuation of HT. Patients with at least 14 hot flashes per week of moderate to severe severity (GCS vasomotor subscore >3, Table 1) were randomized to paroxetine HCl CR 12.5 mg or placebo daily after a 1-week lead-in phase, with the option to titrate to 25 mg daily at Week 2 based on treatment response and tolerability. The primary outcome was change in VMS from baseline to Week 6. Patients in the paroxetine HCl CR group reported significant median reduction in weekly VMS when compared to placebo (6.1 [interquartile range {IQR} =2.7–6.8] vs 2.8 [IQR =0.1–4.5], respectively; P=0.03), with 63% of subjects in the paroxetine HCl CR group titrated to 25 mg daily at Week 2. Changes in the GCS subscore for the reduction in VMS were also noted to be superior for paroxetine (P=0.04), although the authors did not report results. There were no significant differences reported in terms of adverse effects. Similarly to the previous study, strengths include a more general population without a history of breast cancer and use of the CR formulation. Dose titration based on response and tolerability is an additional strength. Important limitations to note include a small sample size, short study duration, variable timelines of previous HT, and a predominantly white population (86%).

More recently, Simon et al10 conducted two similarly designed larger Phase III pivotal clinical trials (614 and 570 patients, respectively) to evaluate the safety and efficacy of low-dose paroxetine mesylate (LDPM) in postmenopausal women with moderate to severe VMS. Participants had to have at least seven to eight hot flashes per day or 50–60 hot flashes per week, a higher frequency than in previously described populations. Patients were randomly assigned to receive paroxetine mesylate 7.5 mg at bedtime or placebo for 12 weeks and 24 weeks, the longest of trial durations to date. The two primary outcomes measured were the changes in mean hot flash frequency and severity (Table 1). Patients had an average of 11.3 hot flashes per day. In both studies, patients in the paroxetine mesylate group had significantly greater reductions in mean weekly VMS frequency at both 4-week (12-week study: −33.0 and −23.5, respectively, P<0.0001; 24-week study: −28.9 and −19.0, respectively, P<0.0001) and 12-week assessments (12-week study: −43.5 and −37.3, respectively, P=0.0090; 24-week study: −37.2 and −27.6, respectively, P=0.0001). The paroxetine mesylate group also had significantly greater reductions in mean weekly VMS severity at Week 4 (P=0.0048) but not at Week 12 (P=0.2893) in the 12-week study, while significant reductions were observed at both Week 4 and Week 12 in the 24-week study (P=0.0452 and P=0.0114, respectively).

To assess the clinical meaningfulness of the reduction in VMS frequency, the PGI-I questionnaire was administered to evaluate the patients’ perception of improvement (Table 1). At Week 4, there were significantly more responders in the paroxetine group than in the placebo group (58.5% vs 47.2%, respectively, P<0.0058), but not at Week 12 (47.8% vs 41.6%, respectively, P<0.1332). An additional outcome in the 24-week study evaluated the persistence of treatment benefit (defined as patients who achieved at least a 50% reduction in moderate to severe hot flash frequency from baseline to Week 24). The benefit of treatment extended through 24 weeks in 47.5% of those in the paroxetine group and 36.3% of women in the placebo group (P=0.0066). Treatment-emergent adverse events were generally similar between paroxetine and placebo groups, with at least a twofold higher frequency of nausea, fatigue, and dizziness reported in the paroxetine group, although all incidences reported were <4%. Additionally, the authors stated that the Discontinuation-Emergent Signs and Symptoms (DESS) scale results did not reveal any meaningful differences between the paroxetine mesylate and placebo group after discontinuation without tapering, although the DESS scale results were not presented.

A major strength of these two trials is the generalizability of results to a relatively healthy population without a history of breast cancer and a majority of participants with naturally occurring menopause. However, the results may be limited for patients with surgically induced menopause. Further strengths include extended study durations, evaluation of a lower dose (7.5 mg) to minimize adverse effects and withdrawal symptoms, a validated real-time electronic hot flash diary, and the exclusion of SERM therapy to limit drug interactions. Two limitations involve the lack of an active comparator arm such as HT and that the study population was predominantly white (70%).

Supplementary publications from this study population presented results on sleep disturbances and evaluated the
effect of treatment on weight and sexual dysfunction in a pooled analysis. Patients reported a baseline mean of 3.6 awakenings per night due to VMS. They found a significant reduction in nighttime awakening due to VMS at 4 weeks (39% reduction for paroxetine vs 28% placebo; \( P=0.0049 \)), and these results were sustained through the 24-week treatment period (62% reduction for paroxetine vs 43% placebo; \( P<0.0001 \)). The paroxetine mesylate group also had significantly increased nighttime sleep duration at all assessments, but no differences were found in sleep-onset latency or sleep-related adverse events such as sedation. In the pooled analysis evaluation of the treatment’s effect on weight and sexual dysfunction, there were no statistically significant changes observed from baseline in terms of weight or sexual function in the paroxetine mesylate 7.5 mg group.

Summary of paroxetine use in populations primarily without breast cancer

In the summarized literature, paroxetine (HCl and mesylate salts) was associated with a 33%–65% reduction in hot flush frequency with 6–12 weeks of treatment compared to 17%–38% reductions with placebo (Table 3). Paroxetine was also associated with significant reductions in hot flush severity and patient-perceived improvement at 4 weeks, although patient-perceived improvement did not remain significant at 12 weeks. A reduction in hot flush frequency was observed within 2 weeks of therapy and persisted throughout a 24-week treatment duration. Although most literature supporting use of paroxetine consists of doses between 10 mg and 25 mg, significant reductions in VMS were observed with the LDPM (7.5 mg/day), with a tolerable adverse effect profile and no significant withdrawal symptoms at discontinuation without tapering.

Discussion

HT is considered to be the most effective treatment for VMS. In women with a history of breast cancer, HT is contraindicated, and alternative therapies, such as SSRIs, are needed to manage VMS. It is important to remember that sometimes the severity of VMS in this patient population can be severe secondary to earlier age of onset, abruptness of onset (chemotherapy induced or surgically induced), and/or use of antiestrogen medications as adjunctive therapy to treat the patient’s breast cancer. Additionally, HT may not be appropriate for patients with contraindications or precautions other than a history of breast cancer, such as those with significant cardiovascular disease, a history of thromboembolism, or conditions exacerbated by HT. Patients may also be unwilling to take HT because of associated risks or lack of tolerability. Due to the limitations of HT, safe and effective alternative therapies are needed.

SSRIs have been utilized and acknowledged by several guideline publications as alternative therapy to HT for the treatment of VMS. Although existing data appear to indicate that HT is more efficacious than SSRIs, the lack of direct comparisons limits this conclusion. RCTs with active comparators are necessary to determine the most effective therapy for VMS. While several SSRIs have been used off-label for alternative therapy, paroxetine mesylate 7.5 mg (Brisdelle®; Noven Therapeutics, LLC) received attention when it was approved for the treatment of moderate-to-severe VMS in the USA. It is important to note the modest treatment benefit when compared to placebo observed in the two RCTs supporting its approval. A majority of the US FDA Advisory Committee for Reproductive Health Drugs panel did not support the approval of paroxetine mesylate for VMS treatment based on its overall risk–benefit profile and modest efficacy. Although the advisory panel’s concerns were taken into consideration, FDA approval was granted due to patients’ perception of benefit, the persistence of treatment effect at 24 weeks, the large avoidance of safety concerns with appropriate patient selection, and the unmet need for nonhormonal therapy options for VMS management.

Paroxetine mesylate offers the lowest available dose of 7.5 mg but is only available in the USA under the brand name Brisdelle® (Noven Therapeutics, LLC). Consequently, this particular formulation is more expensive than other generic paroxetine HCl formulations (Table 4). Although there are minor pharmacokinetic differences between the HCl and mesylate salts, there is no evidence that they have any clinical meaningfulness. The HCl and mesylate salts are both inactive and disassociate from active paroxetine in the gastrointestinal tract. Because both salts have demonstrated efficacy in clinical trials, initiating therapy with paroxetine HCl 10 mg or 12.5 mg CR may be an option when availability or cost is an issue. Paroxetine (HCl and mesylate) exhibits nonlinear pharmacokinetics due to saturable CYP2D6 metabolism, and therefore dose adjustments can lead to disproportional changes in plasma drug levels. Consequently, increases in concentration-dependent adverse effects may be observed with dose increases. Although there are no direct comparisons among the 7.5 mg, 10 mg, and 12.5 mg doses, tolerability is comparable based on adverse event rates in similar patient populations. Moreover, there is currently no head-to-head evidence that doses of 20–25 mg provide significantly greater relief than doses ≤12.5 mg, and the 25 mg dose was associated with increased frequencies of adverse effects.
Table 3  Summary of the literature on paroxetine for treatment of vasomotor symptoms in patients primarily without a history of breast cancer

<table>
<thead>
<tr>
<th>Study design</th>
<th>Patient characteristics</th>
<th>Treatment regimen and duration</th>
<th>Efficacy results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Randomized, double-blind, placebo-controlled trial (n=165)¹¹</td>
<td>Menopausal women with or without history of breast cancer (7% with history of breast cancer); mean age: 54–55 years; mean hot flashes/day: six to seven</td>
<td>Paroxetine HCl CR 12.5 mg or 25 mg daily vs placebo × 6 weeks</td>
<td>Significant decreases in hot flash scores in both 12.5 mg and 25 mg groups vs placebo (62.2% vs 37.8%, P=0.007 and 64.6% vs 37.8%, P=0.03, respectively)</td>
</tr>
<tr>
<td>Randomized, double-blind, placebo-controlled trial (n=56)¹²</td>
<td>Menopausal women; mean age: 56–57 years; median hot flashes/week: 17</td>
<td>Paroxetine HCl CR 12.5 mg daily vs placebo × 6 weeks; may increase to 25 mg daily at 2 weeks based on treatment response and tolerability</td>
<td>Median weekly reductions in hot flashes: 6.1 (IQR: 2.7–6.8) with paroxetine vs 2.8 (IQR: 0.1–4.5) with placebo; P=0.03 GCS scores for VMS also significantly decreased but scores NR; P=0.04 63% increased paroxetine dose to 25 mg/day Mean weekly reductions in hot flashes: 43.5 with paroxetine vs 37.3 with placebo; P=0.009 Hot flash severity scores significantly decreased at Week 4 (P=0.0048) but not at Week 12 (P=0.289) Mean weekly reductions in hot flashes: 37.2 with paroxetine vs 27.6 with placebo; P=0.0001 Hot flash severity scores significantly decreased at both Week 4 (P=0.0452) and Week 12 (P=0.0114) Persistence of treatment effect was observed in 47.5% with paroxetine vs 36.3% with placebo at 24 weeks (P=0.0066)</td>
</tr>
<tr>
<td>Randomized, double-blind, placebo-controlled trial (n=614)¹³</td>
<td>Postmenopausal women with moderate-to-severe VMS; median age: 54 years; mean hot flashes/day: eleven</td>
<td>Paroxetine mesylate 7.5 mg daily vs placebo × 12 weeks</td>
<td></td>
</tr>
<tr>
<td>Randomized, double-blind, placebo-controlled trial (n=570)¹⁴</td>
<td>Postmenopausal women with moderate-to-severe VMS; median age: 54 years; mean hot flashes/day: eleven</td>
<td>Paroxetine mesylate 7.5 mg daily vs placebo × 24 weeks</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: CR, controlled release; GCS, Greene Climacteric Score; HCl, hydrochloride; IQR, interquartile range; NR, not reported; VMS, vasomotor symptoms.
Table 4 Available paroxetine formulations in the USA and associated cost

<table>
<thead>
<tr>
<th>Drug</th>
<th>Available formulations</th>
<th>AWP cost (30-day supply)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paroxetine HCl</td>
<td>Generic 10 mg, 20 mg, 30 mg, 40 mg tablets</td>
<td>$78.56 (10 mg)</td>
</tr>
<tr>
<td></td>
<td>Generic CR 12.5 mg, 25 mg, 37.5 mg tablets</td>
<td>$108.63 (12.5 mg)</td>
</tr>
<tr>
<td></td>
<td>*Paxil 10 mg, 20 mg, 30 mg, 40 mg tablets</td>
<td>$163.85 (10 mg)</td>
</tr>
<tr>
<td></td>
<td>*Paxil CR 12.5 mg, 25 mg, 37.5 mg tablets</td>
<td>$168.76 (12.5 mg)</td>
</tr>
<tr>
<td></td>
<td>*Paxil 10 mg/5 mL suspension</td>
<td>$284.45 (250 mL)</td>
</tr>
<tr>
<td>Paroxetine mesylate</td>
<td>*Briselle 7.5 mg capsules</td>
<td>$161.64</td>
</tr>
<tr>
<td></td>
<td>*Pexeva 10 mg, 20 mg, 30 mg, 40 mg tablets</td>
<td>$265.74 (10 mg)</td>
</tr>
</tbody>
</table>


Abbreviations: AWP, average wholesale price; CR, controlled release; HCl, hydrochloride.

Therefore, it is prudent to initiate therapy at the lowest available dose and only consider a dose titration in patients with an insufficient response after an adequate trial (ie, 2 weeks) because some patients may benefit from dose increases.12

The most common adverse effects reported in the studies10–15 include somnolence, fatigue, headache, gastrointestinal effects (which include nausea, increased appetite, and constipation), dry mouth, insomnia, weight gain, and weakness. These are similar to adverse effects commonly reported with paroxetine use in other patient populations. The serotonin-mediated adverse effects are considered to be dose dependent.35 If the patient experiences fatigue or somnolence, the medication should be administered at bedtime. For patients receiving doses >7.5 mg for at least 1 week, it is recommended to taper therapy to discontinuation to limit common withdrawal symptoms such as headache, agitation, and sleep disturbances.35 Patients should be monitored for common adverse effects during treatment as well as for discontinuation-emergent symptoms. Other important precautions associated with paroxetine therapy include CYP2D6 drug interactions, increased fracture rate, and possible serotonin syndrome due to pharmacodynamic interactions with other agents that affect serotonin levels.35

Finally, RCTs with active comparators are still needed to determine efficacy relative to HT.

Conclusion

The current evidence indicates that paroxetine (HCl and mesylate) is a safe and effective therapy for the treatment of VMS that may accompany menopause regardless of a history of breast cancer. Paroxetine HCl or mesylate (7.5–12.5 mg/day) should be considered a first-line therapy option for VMS in patients for whom HT is either inappropriate or intolerable. RCTs with active comparators are still needed to determine the most effective treatment for VMS. It is recommended to use the lowest available dose to minimize adverse effects and discontinuation-emergent symptoms. Patient-specific characteristics and treatment needs should be considered to individualize treatment and monitor for adverse effects.

Disclosure

The authors report no conflicts of interest in this work.

References